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Japanese encephalitis virus (JEV) causes Japanese encephalitis, which is a leading form of
viral encephalitis in Asia, with around 50,000 cases and 10,000 deaths per year in children
below 15 years of age. The JEV has shown a tendency to extend to other geographic regions.
Case fatality averages 30% and a high percentage of the survivors are left with perma-
nent neuropsychiatric sequelae. Currently, there is no cure for JEV, and treatment is mainly
supportive. Patients are not infectious, but should avoid further mosquito bites. A num-Epidemiology
Pathogenesis
Vector born diseases
Epidemics
ber of antiviral agents have been investigated; however, none of these have convincingly
been shown to improve the outcome of JEV. In this review, the current knowledge of the
epidemiology and the pathogenesis of this deadly disease have been summarized.
about every ten years; in 1924, over 6,000 cases were docu-
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Japanese encephalitis (JE) is a common mosquito borne ﬂa-
viviral encephalitis. It is one of the leading forms of viral
encephalitis worldwide, mostly prevalent in eastern and
southern Asia, covering a region with a population of over
three billion.1 Most infections of JE are asymptomatic, but
if clinical illness develops, it causes signiﬁcant morbidity
and mortality. Though underreported, JE causes an estimated
50,000 cases and15,000deaths annually.2 JE is a disease of pub-
lic health importance because of its epidemic potential and
high fatality rate. In endemic areas, the highest age-speciﬁc
attack rates occur in children of 3 to 6 years of age.3,4 Approxi-
mately one third of patients die, andhalf of the survivors suffer
severe neuropsychiatric sequelae from the disease.5Japanese encephalitis virus (JEV) belongs to the family
ﬂaviviridae and genus Flavivirus.6 It is a single stranded,
positive-sense polarity RNA genome of approximately 11kb in
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Este é um artigo Open Access sob a licençalength. The virion of JEV contains three structural proteins –
nucleocapsid or core protein (C), non-glycosylated membrane
protein (M), and glycosylated envelope protein (E), as well as
seven non-structural (NS) proteins – NS1, NS2A, NS2B, NS3,
NS4A, NS4B, and NS.7 JEV exists in a zoonotic cycle between
mosquitoes and pigs and/or water birds. This study reviewed
JEV literature from 2000 to 2010, outlining the Indian sce-
nario, clinical depictions, diagnosis, and the prevention of this
deadly disease.
Historical perspective
The ﬁrst outbreak of encephalitis attributed to JEV was
reported in Japan in 1871. Major epidemics have been reportedhi Post Graduate Institute of Medical Sciences, Rai Barelly Road
mented in a severe epidemic in Japan.8 In 1935, the prototype
Nakayama strain was isolated from the brain of a patient
suffering from encephalitis. Thereafter, the virus had been
 de CC BY-NC-ND
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lassiﬁed with other ﬂaviviruses as a group B arbovirus in
he family Togaviridae, Originally the term “type B” encephali-
is was used to distinguish this summer epidemic from von
conomo’s lethargica/sleepy sickness, commonly known as
ype A encephalitis,5 which occurs in winter with a different
linical presentation. Later on, the designation “type B” was
bandoned, and in 1985, JEV was designated under a sepa-
ate family Flaviviridae, as a member of genus Flavivirus.9 The
enus Flavivirus has been named after the prototype yellow
ever virus (from the Latin word ﬂavi,), and is comprised of 70
mall, enveloped viruses with single stranded positive-sense
NA.5
pidemiological features
lobal outlook
apanese encephalitis is one of the most important forms of
pidemic and sporadic encephalitis in the tropical regions
f Asia, including Japan, China, Taiwan, Korea, Philippines,
ll of Southeastern Asia, and India; however, related neu-
otropic viruses are spread across the globe.10 Countries with
roven epidemics of JE include India, Pakistan, Nepal, Sri
anka, Burma, Laos, Vietnam, Malaysia, Singapore, Philip-
ines, Indonesia, China, maritime Siberia, Korea, and Japan.11
n the past 50 years, the geographic areas affected by JEV have
xpanded (Fig. 1). Epidemic activity in Northern India, Central
ndia, and Nepal has increased since the early 1970s. In the
990s, the virus continued to spread in Pakistan,12 in the Kath-
andu valley of Nepal,13 and also in continental Australia.14
E is primarily found in Southeast Asian countries. Three epi-
emiological regions can be distinguished. First, the endemic
egion composed of Southern India, Southern Vietnam,
outhern Thailand, the Philippines, Malaysia, and Indone-
ia. Secondly, the intermediary subtropical region, which
ncludes Northern India, Nepal, North and Central Burma,
orthern Thailand, Northern Vietnam, Southern China, and
angladesh. Thirdly, the temperate epidemic region, span-
ing Northern China, Korea, Japan, Taiwan, and the southern
xtremities of Russia. Transmission is variable, and is coupled
ith environmental temperature. During winter, mosquitoes
re inactive, but huge epidemics can happen during summer
nd autumn. The geographical area of this disease is showing
trend towards expansion. Postulated explanations are bird
igration, certain irrigation projects, animal smuggling, and
lobal warming. Development of rice plantations is theoreti-
ally foreseeable in other regions (Pakistan, Afghanistan, Nile
alley, Madagascar, and Oriental Africa), creating a favorable
nvironment for further vector proliferation.15
roblem in India
n India, epidemics of JE are reported from many parts of the
ountry, and it is considered a major pediatric problem. The
rst recognition of JE based on serological surveys was in 1955,
n Tamil Nadu, India.16 A total of approximately 65 cases were
eported between 1955 and 1966 in Southern India.17 Subse-
uent surveys carried out by the National Institute of Virology2;16(6):564–573 565
of Pune indicated that approximately half of the population
in Southern India has neutralizing antibodies to the virus.
Since 1955, many major outbreaks in different parts of the
country have been reported. A major outbreak resulting in
a 42.6% fatality rate was reported in the Bankura District of
West Bengal in 1973. Subsequently, the disease spread to other
states and caused a series of outbreaks in different parts of
the country. In 1978, cases were reported from 21 states and
union territories.15 In Uttar Pradesh, the ﬁrst major JE epi-
demic occurred in Gorakhpur in 1978, with 1,002 cases and 297
deaths reported. Many outbreaks were reported in Gorakhpur
after the 1978 JE outbreak, with varying intensity and mag-
nitude. Since 1978 to 2005, this encephalitis has taken more
than 10,000 lives in the state.18 The 2005 epidemic surpassed
all previous reported outbreaks in the country. In that year,
Uttar Pradesh faced a devastating outbreak of JE, mostly con-
ﬁned to Gorakhpur, with 6,061 cases and 1,500 deaths; another
outbreak occurred in 2006, with 2,320 cases and 528 deaths.
Similarly, JE cases in Uttar Pradesh were conﬁned predomi-
nantly to Gorakhpur during 2007, with 3,024 cases and 645
deaths,18 and then onwards till 2007 there have been 103,389
reported cases in India, and 33,729 deaths.19 Approximately
597,542,000 people in India live in JE-endemic regions, and
1,500 to 4,000 cases are reported every year.20 These ﬁgures are
based on total reported cases; it is possible that many cases
are unreported and hence the actual magnitude of the threat
of JE may be considerably higher, both in the Indian and in
the global context. JE incidence during the past few years is
given in Table 1.21 The trend of JE suggests that the problem in
Northern India is escalating, and larger epidemics may occur
in the future.22
Vector and transmission
The JEV is transmitted to vertebrates bymosquitoes. Mosquito
transmission was suspected during the early 1930s; in 1938,
Mitamura et al. reported isolation fromCulex tritaeniorynchus.23
The ecology of JEV has come from various studies carried
out in Japan by Scherer et al.,24 and JEV ecology has been
the subject of several reviews.11,25,26 Many species of Culex
mosquitoes can transmit JE. For Southern Asia, Eastern Asia,
and Southeastern Asia, the main vector of JE is C. tritae-
niorhynchus. For Northern Australia, the main vector is C.
annulirostris. However, various other secondary vectors may
be important. Indian studies in particular have revealed a
number of secondary vectors, including Mansonia indiana, C.
pseudovishnui, C. whitmorei, C. gelidus, C. epidesmus, Anopheles
subpictus, A. peditaeniatus, and M. uniform.27 The natural cycle
of JE virus in Asia involves water birds and Culex mosquitoes.
However, unlike many other mosquito-borne diseases, an
amplifying host is important in the epidemiology of human JE.
In Asia, pigs are considered to be themost important amplify-
ing host, providing a link to humans through their proximity
to housing.28 The life cycle of the virus is illustrated in Fig. 2.
There are two epidemiological patterns of transmission: an
endemic pattern in tropical areaswith viral circulation inmost
months of the year, but with a broad seasonal peak, probably
resulting from irrigation practices; and an epidemic pattern
in more temperate areas with clear summer seasonality.11,29
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Fig. 1 – Global distribution of known Japanese encephalitis virus infection and risk areas.
Table 1 – Incidence of Japanese encephalitis in India.
Sl. No. Affected States/UTs 2004 2005 2006 2007 2008 2009(P) 2010(P)
C/D C/D C/D C/D C/D C/D C/D
1 Andhra Pradesh 7/3 34/0 11/0 22/0 6/0 14/0 132/1
2 Assam 235/64 145/52 392/119 424/133 319/99 462/92 274/59
3 Bihar 85/28 192/64 21/3 336/164 203/45 325/95 19/0
4 Delhi 17/0 6/0 1/0 0/0 0/0 0/0
5 Goa 0/0 4/0 0/0 27/0 39/0 66/3 23/0
6 Haryana 37/27 46/39 2/1 32/18 13/3 12/10 0/0
7 Karnataka 181/6 122/10 73/3 32/1 3/0 246/8
8 Kerala 9/1 1/0 3/3 2/0 2/0 3/0 19/5
9 Maharashtra 22/0 510 1/0 0/0 24/0 1/0 0/0
10 Manipur 0/0 1/0 0/0 65/0 4/0 6/0 111/5
11 Nagaland 0/0 0/0 0/0 7/0 0/0 9/2 11/6
12 Punjab 0/0 1/0 0/0 0/0 0/0 0/0
13 Uttrakhand 0/0 0/0 0/0 0/0 12/0 0/0
14 Tamil Nadu 88/9 51/11 18/1 37/0 144/0 265/8 242/3
15 Uttar Pradesh 1030/228 6061/1500 2320/528 3024/645 3012/537 3073/556 1065/172
16 West Bengal 3/1 12/6 0/0 16/2 58/0 0/0
Total 1714/367 6727/1682 2842/658 4024/963 3839/684 4482/774 1896/251
C, cases; D, deaths; P, provisionally acute encephalitis syndrome cases.
braz j infect d i s . 201
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Fig. 2 – Transmission cycle of the Japanese encephalitis
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material has shown diffuse infection throughout the brain,irus.
esides mosquitoes, birds also spread the virus to new geo-
raphic areas.
ortality and morbidity
E’s mortality rate is approximately 25% to 30%.1,29 Although
ntensive care support can reduce the mortality rate, patients
ften suffer signiﬁcant long-term morbidity. Some effects,
uch as learning difﬁculties and behavioral problems, can be
ubtle and may remain undetected for several years.30,31 50%
f those who recover suffer from neurological deﬁcit.32 Over
he past 60 years, it has been estimated that JEV has infected
ore than tenmillion people, of whom threemillion died and
our million suffered long-term disabilities.29
ecurring pattern
enerally, two epidemiological patterns of JE are
ecognized.29,33 In northern temperate areas (Japan, Tai-
an, China, Korea, Northern Vietnam, Northern Thailand,
epal, and Northern India), large epidemics occur during the
ummer months, roughly from May to October.34 In southern
ropical areas (Southern Vietnam, Southern Thailand, Indone-
ia, Malaysia, Philippines, Sri Lanka, and Southern India), JE
ends to be endemic; cases occur sporadically throughout the
ear, with a peak after the start of the rainy season (July to
eptember). In India, the state of Karnataka experiences two
pidemics each year, with a severe form from April to July
nd a milder one from September to December along with
he rest of India.11
arget population
E is mostly a disease of children and young adults. Rates of
nfection in the 3 to 15 year age group are ﬁve to ten times
igher than in older individuals, because of high background
mmunity in older individuals. Epidemics in non-endemic
egions have affected all age groups, but a bimodal age2;16(6):564–573 567
distribution (young children and elderly) has appeared, indi-
cating an increased risk in elderly people.23 In endemic areas,
nearly all residents have sustained infection by young adult-
hood. The ratio of unapparent to apparent infections is 200:1
to 300:1.35 An excess of cases has been noted inmales inmany
outbreaks; presumably because of increased exposure in areas
of rice cultivation.23
Prevalence of the disease
Almost half of the human population now lives in countries
where the disease is endemic. The annual incidence of the
disease is of 30,000 to 50,000 cases,1 and the annual num-
ber of deaths reported is 10,000 to 15,000.33,36 The disease
can cause irreversible neurological damage.36 A fatality rate
of 30% to 50% has been attributed to JE in Southern and East-
ern Asia. A large proportion of survivors, 30% to 60% of the
cases, suffer from long-term neurological manifestations in
the form of convulsions, tremors, paralysis, ataxia, and other
such symptoms.28,34 Annual incidence ranged between 1,765
and 3,428 cases and deaths ranged between 466 and 707 in
India, according to the National Vector Borne Disease Control
Programme of the Ministry of Health and Family Welfare.
Clinical depiction of JE
Pathogenesis
The incubation period of JEV ranges between six and 16 days.
The factors determining who of all the infected develop the
disease are unknown, but could include viral factors such as
route of entry, titer, and neurovirulence of the inoculum, and
host factors such as age, geneticmake-up, general health, and
pre-existing immunity. After the bite of an infected mosquito,
the virus replicates in the skin and is then transported to
regional lymph nodes. In most Flavivirus infections including
dengue virus, and West Nile virus, Langerhans dendritic cells
in the skin are reported to support viral replication.37,38 Next,
it ampliﬁes peripherally, causing a transient viremia before
invading the central nervous system (CNS).39 During primary
viremia, viral particles are seeded in the extraneural tis-
sues. Major extraneural sites of replication include connective
tissue, skeletal muscle, myocardium, smooth muscle, lym-
phoreticular tissues, and endocrine and exocrine glands. From
the blood, the virus penetrates into the CNS. The clinicalman-
ifestations of many infections are dependent on whether or
not the virus gains access to susceptible cellswithin theCNS. If
the infection is limited to extraneural tissues, the signsmay be
mild or inapparent; however, infection of neural tissues by the
same agent leads to encephalitis. Therefore, the mechanism
by which the virus penetrates the CNS is of prime impor-
tance in understanding the pathogenesis of viral diseases.40,41
How JEV crosses the blood-brain barrier is unknown.5 How-
ever, immunohistochemical staining of human postmortemindicating ahematogenous route of entry.42,43 Althoughexper-
imental evidence suggests that replication within endothelial
cells may be an important means of crossing the blood-brain
i s . 20568 braz j infect d
barrier in some ﬂaviviruses, for JEV, passive transfer across the
endothelial cells appears to be amore likelymechanism.5,40,41
Other factors that compromise the integrity of the blood-brain
barrier have also been implicated as risk factors for neuroin-
vasion. Several studies reported a disproportionate number of
fatal cases had neurocysticercosis at necropsy.5,44
Clinical signs and symptoms
Infection due to JEV is most often asymptomatic.10 On aver-
age, only one in 300 cases produce clinical symptoms. The ﬁrst
signs of infection appear after an incubation period between
six and 14 days. It usually starts with a fever above 38◦ C,
chills, muscle pain, andmeningitis-type headaches accompa-
nied by vomiting. The initial presentation in children usually
beginswith gastrointestinal symptoms: nausea, vomiting, and
abdominal pains similar to those found in an acute abdominal
syndrome.23 These may include confusion, paralysis, Parkin-
sonian movement disorders, abnormal posturing, seizures,
and coma.45 A proportion of patients with JE have an acute
ﬂaccid paralysis that is easilymistaken for poliomyelitis,46 but
the majority present with a reduced level of consciousness,
oftenheralded by generalized convulsions. Fatality is observed
in 20 to 30% of the cases, with signs of acute cerebral edema or
severe respiratory distress from pulmonary edema. Recovery
usually leaves serious behavioral and neurological sequelae,
most notably persistently altered sensorium, extrapyramidal
syndrome, epileptic seizures, and severe mental retardation
in children. The duration of the coma is associated with
repetitive seizures, peduncular damage, or intracranial hyper-
tension, which are considered poor prognostic factors, leading
to fatality.47 The course of disease may be divided into four
stages. The ﬁrst is the prodromal stage, which is charac-
terized by an abrupt onset of high fever accompanied by
headache, with non-speciﬁc symptoms including malaise,
anorexia, nausea, and vomiting. The second is acute stage,
which includes changes in the level of consciousness ranging
from mild clouding to stupors, semi-coma, or coma. Gener-
alized or focal convulsions are common, with neck stiffness
andweakness of extremities. In this stage, fatal cases progress
rapidly and die. The third is a late stage characterized by
defervescence with improved neurologic sequelae in uncom-
plicated cases. The last stage is the sequelae phase, which
includes complete recovery in mild cases, while severe cases
also improve, but are left with neurological deﬁcits.
Pathology
Several pathological ﬁndings in JE are documented. The main
alteration is of the neurological system.8,48 In animal mod-
els, nonsuppurative encephalitis could be experimentally
induced in piglets inoculated with JE.49 JE predominately
affects the thalamus, anterior horn cells of the spinal cord,
cerebral cortex, and cerebellum.50 During the acute stage of
illness, congestion, edema, and herniation are found in the
brain. Microscopic lesions include meningeal inﬂammation,
perivascular lymphocytic cufﬁng, neuronal degeneration
and neuronophagia, and microglial proliferation forming
glial nodules. These changes usually occur in gray matter
and predominantly affect diencephalic, mesencephalic, and12;16(6):564–573
brainstem structures. Immunohistochemical studies of
human fatal cases have shown a different topographic dis-
tribution of JEV in the brain.43,51 JE virus antigen can be
immunohistochemically detected in the cytoplasm of the
nerve cells in the cortex of the frontal and temporal lobes,
and in the gray matter of the thalamus and midbrain.49 At
necropsy, CNS ﬁndings in JE reﬂect the inﬂammatory response
to widespread neuronal infection with a virus.5,8,13,43 The
leptomeninges are normal or hazy. The brain parenchyma
is congested with focal petechiae or hemorrhage in the grey
matter. Blotchy necrolytic zones are seen when survival
is prolonged beyond seven days. The white matter usu-
ally appears normal. In some patients, the grey matter of
the spinal cord is conﬂuent discolored, resembling that of
poliomyelitis.5,52 In humans, a characteristic involvement of
bilateral thalami can be seen by diffusion-weighted imaging.
Magnetic resonance imaging lesions can also be detected in
basal ganglia, midbrain, Pons, cerebellum, cerebral cortex,
and subcortical white matter. After recovery from acute
encephalitic illness, these cases usually manifest clinically
with typical Parkinsonian features.53 In addition to brain
lesion, the involvement of anterior horn cells can be found as
previously mentioned.54,55 The distribution of cell types does
not vary between the ﬁrst and the last day of hospitalization,
is similar in fatal and nonfatal cases, and is unaffected by
administration of steroids.56
Diagnosis
Patients with JE present vivid signs of acute encephalitic syn-
drome. There are many possible causes of acute encephalitic
syndrome; thus, laboratory conﬁrmation is essential for the
accurate diagnosis of JE, which is not a simple process due
to the very low viremia.1 Diagnosis of JE can be made by virus
isolation in cell/tissue culture, antigendetection, andantibody
detection.
Culture
Japanese encephalitis virus can be isolated by intracerebral
inoculation of clinical specimens in the suckling mouse brain.
Various cell cultures that have been used more recently
include primary chick, duck embryo cells, and lines of Vero,
LLCMK2, C6/36, PK, and AP61 cells. The virus can be isolated
from the blood of patients in the preneuroinvasive and neu-
roinvasive phases of the illness, usually not later than six or
seven days after the onset of symptoms.50,57
Antigen detection
Various studies have proved the efﬁcacy of antigen detec-
tion in CSF using reverse passive hemagglutination,58
immunoﬂuorescence,59 and staphylococcal coagglutination
tests using polyclonal or monoclonal antibodies60 in rapid
diagnosis of JE. Modiﬁed techniques, such as M-IGSS, have
been successfully used in the detection of antigen in
mononuclear cells of peripheral blood and CSF of patients.61
Immunohistochemistry has been used to identify viral
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the strain from which these are produced are given in
Table 2.
Table 2 – Vaccines against Japanese encephalitis.
Vaccine Strain Efﬁcacy
Inactivated mouse brain NakayamaBeijing-1 91%
Inactivated primary hamster P-3 85%braz j infect d i s .
ntigens in the CNS. Histopathology examination is also very
elpful for clinical correlation and diagnosis of JEV.
ntibody detection
gM capture enzyme-linked immunosorbent assay (ELISA) has
een the most widely used diagnostic methods for JEV anti-
ody detection.62 At present, much advancement has been
chieved with methods for the early detection of JEV, such as
he dipstick method63 and JEVCheX.64
CR diagnosis
eal-timepolymerase chain reaction (PCR) assays provide sen-
itivity and speciﬁcity equivalent to that of conventional PCR
ombined with Southern blot analysis, and since ampliﬁca-
ion and detection steps are performed in the same closed
essel, the risk of releasing ampliﬁed nucleic acids into the
nvironment is negligible. In general, both PCR and ampli-
ed product detection are completed within an hour or less,
hich is considerably faster than conventional PCR detec-
ion methods. By reverse transcriptase PCR, the viral genome
an be ampliﬁed directly from tissue or blood.15,65 A novel
ested reverse transcription-polymerase chain reaction (RT-
CR)-based kit is described for detecting JEV, in which all
eagents are lyophilized in reaction tubes and control RNA is
ncluded in each reaction to monitor false negative results.66
Another study described and evaluated a reverse transcrip-
ion loop-mediated isothermal ampliﬁcation (RT-LAMP) assay
or detecting JEV. The sensitivity of the JEV RT-LAMP assay
as in concordance with that real-time RT-PCR, and it was
ore sensitive than that of conventional RT-PCR. The JEV RT-
AMP was highly speciﬁc; no cross-reactivity was found with
engue-2 virus, rabies virus, norovirus, astrovirus, and human
nterovirus 71. The JEV RT-LAMP assay was simpler and less
ime-consuming compared to the conventional RT-PCR and
eal-time RT-PCR. The results suggest that the RT-LAMP assay
an be applied as a practical molecular diagnostic tool for JEV
nfection and surveillance.67
reatment
here is no cure for JE and treatment is mainly supportive.
atients are not infectious, but should avoid further mosquito
ites.31 A number of antiviral agents have been investigated,
ncluding INF alfa-2a68 and diethyldithiocarbamate (a low
olecular weight dithiol).69 However, none of these have
onvincingly been shown to improve the outcome of JE. Effec-
ive supportive management has been shown to improve the
utcome.50 The standard management of viral encephalitis
hould be used.70 Mannitol might be used to reduce intracra-
ial pressure. A signiﬁcant research on minocycline as an
nti-JEV drug is an in vivo study that showed that minocy-
line reduces neuronal apoptosis, microglial activation, active
aspase activity, proinﬂammatory mediators, and viral titer
arkedly on the ninth day after infection.71 Another com-
ound that has shown inhibition of JEV replication completely
n vitro is anN-methyl isatin-b thiosemicarbazonederivative.722;16(6):564–573 569
Supportive nursing care and prevention of infection during
hospitalization are important. Close monitoring is necessary
for the physiological disturbances during hospitalization and
for sequelae after discharge.
Prevention and control
The prevention of JE is based largely on two interventions;
mosquito control, and by an immunization system.
Vector control
Vector control is important in primary prevention. To control
the vector population, classical methods such as insecti-
cide and bed nets are widely applied in endemic areas.50
Thermal fogging with ultra low volume insecticides such as
pyrethrum or malathion has been recommended for the pre-
vention of local transmission during epidemics, particularly
in peri-urban areas with marshes. However, the vastness of
breeding areas makes larvicidal measures currently imprac-
ticable. Effective measures undertaken in some countries to
prevent or inhibit larval development include novel water
management and irrigation practices such as periodic lower-
ing of the water level, intermittent irrigation, and constant
ﬂow systems. Vector control alone cannot be relied upon to
prevent JE since it is almost impossible to control mosquito
density in the rural areas, which are the worst affected due to
poor socioeconomic conditions. Thus, JE control through vec-
tor control methods is limited by the sustainability and cost
effectiveness of the program.73
Immunization
To prevent JE, it is necessary to implement a large-scale
immunization of the susceptible human population. Vac-
cination provides active immunity against JEV. There are
several groups of vaccines which are currently in use: puri-
ﬁed, formalin-inactivated mouse-brain derived, cell-culture
derived inactivated, and cell-culture derived live attenuated.15
Formalin-inactivated vaccines have been safe and effec-
tive against JEV for at least 30 years.74 Of these, the
most widely produced and internationally distributed is the
mouse-brain derived inactivated vaccine. The efﬁcacy andkidney cells
Live attenuated primary
hamster kidney cells
SA 14-14-2 >95%
i s . 20570 braz j infect d
Puriﬁed, formalin-inactivated
mouse-brain-derived JE vaccine
Mouse-brain derived inactivated vaccines are based on the
Nakayama and Beijing-1 strains (seroconversion rate 80%
to 90%). This is the only vaccine against JE approved by
the World Health Organization. The vaccine produced from
the original Nakayama strain is manufactured in Japan, and
was licensed in 1954. It is available internationally under
the Biken label.11,23 This vaccine is also independently pro-
duced in China, India, Thailand, and Taiwan. The Central
Research Institute in Kasauli is the manufacturer in India. It
is available in lyophilized form, in which gelatin and sodium
glutamate are used as stabilizers, and thimerosal is used as a
preservative.75
The primary vaccination is done between the ages of 1 and
3 at doses of 0.5mL to 1mL (0.25 to 0.5 with children under age
3) subcutaneously. The dose regimen consists of one injection
on days zero, seven, and 30 with a booster after one year and
thereafter every three years until age 10. The protective efﬁ-
cacy is above 90%.15 Due to its high production cost, lack of
long-term immunity, and adverse allergic reactions, this vac-
cine is not practical to be administered in poor rural areas,
where it is urgently needed. These difﬁculties have led to the
development of improved vaccines.
Inactivated hamster kidney cell-culture-derived
JE vaccine
This vaccine is based on the Beijing-3 strain of JEV.15 In China,
an inactivated vaccine produced in primary hamster kidney
(PHK) cell culture was developed and has been in use since
1967. It has relatively fewer side effects and is easy to man-
ufacture. In an extensive randomized ﬁeld trial in China, its
efﬁcacy was found to range between 76% and 90%.34 In the
last decade, aVero cell-culture based inactivated vaccineusing
various local JEV isolates has also been developed and is
undergoing clinical trials. AVero-cell culturederived formalin-
inactivated vaccine is being developed using an attenuated
SA14-14-2 strain, and it has induced high titers of neutralizing
antibodies in mice after two injections.76 Recently, Vero-cell
culture derived formaldehyde inactivated JE vaccine using
P20778 (Indian isolate) has been developed, and has gen-
erated high titers of anti-JEV antibodies in mice; sera from
immunizedmiceneutralizeddifferent JEV strainswith varying
efﬁcacies.77
Cell-culture derived live attenuated JE vaccine
The ChimeriVax-JE has been available since 2001.78 Live atten-
uated vaccine appears to offer great prospects for future
vaccine development, since less virus is needed to trigger
a satisfactory immune response, which makes the vaccine
cheaper, and fewer doses are required, which makes it easy
to administer.512;16(6):564–573
Vaccine based on the SA14-14-2 strain
This is an attenuated and genetically stable strain that in
large-scale case–control studies in China has shown 95% pro-
tection after two doses with an interval of one year.15 In the
1980s, China developed this live attenuated vaccine named
SA 14-14-2 by passaging the SA14 strain of JEV in PHK cells.
Six amino acid changes in E protein and three in NS genes
were associated with the attenuation.79 Recently, another
case–control study in Nepal showed that a single dose of this
vaccine induced an efﬁcacy of 98%.80 A study on the long-term
efﬁcacy (over ﬁve or ten years) is needed to know if the sin-
gle dose is sufﬁcient or if boosters are necessary for long-term
immunization of the targeted population.
Adverse reactions
There are several side effects of JE vaccination. Local side
effects include tenderness, redness, and swelling. Sometimes
systematic adverse reactions are also noted after vaccination,
such as headache, myalgia, abdominal pain, or skin rash.15
Occasionally local hypersensitivity reactions (erythema or
edema at the injection site) can be observed in some chil-
dren. Other reactions, such as generalized urticaria, facial
angioedema, and respiratory distress have been reported in a
fewpeople fromnon-endemic zones after vaccination.15 Some
recipients of the vaccine had, very rarely, major neurologi-
cal side effects (1 to 2.3 per million recipients: encephalitis,
seizures, and peripheral neuropathy).10
Other JE vaccines under development
Several vaccines are still in various stages of development.
These include: recombinant protein based vaccines, recombi-
nant virus based/chimeric vaccine, and DNA vaccines. Second
generation recombinant vaccines are in developmentwith the
aim of improving immunogenecity and decreasing adverse
reactions.50
JE vaccination in India
The JE vaccination campaign was launched during 2006
wherein 11 of the most sensitive districts in Assam, Kar-
nataka and Uttar Pradesh were covered. Altogether, 86 JE
endemic districts in the states of Assam, Andhra Pradesh,
Bihar, Haryana, Goa, Karnataka, Kerala, Maharashtra, Tamil
Nadu, Uttar Pradesh, and West Bengal have been covered. Re-
orientation training course on AES/JE case management is a
continuing process. Such orientating training courses were
carried out in Andhra Pradesh, Assam, Haryana, Karnataka,
Tamil Nadu, Uttar Pradesh, and West Bengal during 2008 and
2009.18Conclusion
Japanese encephalitis is a public health problem, not only for
Asia but for the entire world. However, JE is rising throughout
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sia, because epidemics are typically noticed only after out-
reaks, and because the disease may go largely unobserved
n endemic regions. Environmental and ecological factors are
esponsible for the spread of JEV. There is no speciﬁc treatment
or JE; only prevention can control the disease. Control may be
ossible only after developing a strong surveillance system
ogether with a high-quality immunization program. Imple-
entation of a vaccination program for young children, as
ell as modiﬁed agricultural practices, pig vaccination, rigor-
usmonitoring, vector control, and improved living standards
an reduce the number of JE cases.
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